Page 16 - Pharmaceutical

AbbVie opens small molecule API facility in Singapore

The facility, which marks AbbVie's first manufacturing presence in Asia, is the first phase of the project to develop a production site in Singapore which will also house a biologics facility

US FDA issues thirteen 483 observations for Alkem's Daman facility

Observations were issued to the company following US drug regulator's inspection at its manufacturing facility at Daman from September 20 to September 29, 2016

Non-availability of D-penicillamine disrupts Panacea Biotec's Cilamin capsule supply

The company, which recently released limited quantities of the medicine in the market, is holding talks with Indian and China raw material suppliers to normalise the situation

Systech eyes growth in Indian pharma sector as traceability gains traction

With developed countries enacting stringent serialisation and tracing regulations, the company aims to capitalise on India's booming pharmaceutical market

Kilitch Drugs allotted land in Ethiopia to set up production facility

The company has been looking to expand its presence in Africa with plans to set up manufacturing facilities in Ethiopia and Burkina Faso primarily for nutraceuticals

Suven Life secures patents for CNS drug in India and Japan

These patents are valid through 2026 and 2032 in India and Japan, respectively

Syngene closes deal to buy Strand Life's bioinformatics platforms

The deal to boost Syngene's bioinformatics and data analytics capabilities

Indoco Remedies buys Micro Labs' manufacturing facility in Baddi

The acquired facility, which produces 4.3 billion tablets and 50 million capsules per annum, is close to Indoco's existing manufacturing plant in Baddi

Suresh Subramanian to head Biocon's branded formulations business in India

He has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline, Novartis, AstraZeneca and Pfizer

Zydus partners with Japan's Takeda to develop vaccine for chikungunya

Early stage project will develop a vaccine for chikungunya, for which there is currently no vaccine or medicine to treat it

Glenmark inks pact with Lubrizol arm Particle Sciences to develop generic cancer drug

As per the deal, Glenmark will have global exclusive marketing rights of the product - a generic version of cancer drug Abraxane that had worldwide sales of $ 967 million in 2015

Themis Medicare joins hand with Nevakar to tap US pharma market

As per the deal, Themis will develop a selected number of injectable products that will be manufactured and commercialised by Nevakar in the US and select global markets

Horizon Pharma buys Raptor Pharmaceutical for $ 800 million

The deal will strengthen Irish firm's focus on rare diseases and expand its operations in Europe and other international markets

Thermo Fisher opens clinical services facility in South Korea

Over the past few years, clinical trials have consistently grown in South Korea, making it a leading emerging nation for clinical trial research in Asia

Asahi Glass buys German biopharmaceutical CMO Biomeva

With this acquisition, AGC's life science business will be able to expand its geographic coverage and offer a wider range of capacities

Aralez acquires US and Canadian rights to Zontivity from Merck

Zontivity is the first and only approved therapy shown to inhibit the protease-activated receptor-1, the primary receptor for thrombin, which is considered to be the most potent activator of platelets

Glenmark receives US FDA approval for skin ointment lidocaine

The approved product is the generic version of AstraZeneca's Xylocaine ointment (5%), which recorded annual sales of approximately $ 373 million

Skin care specialist Kaya Ltd acquires 75% stake in two UAE firms

The company has acquired 75 percent stake in Minal Medical Centre, Dubai, and Minal Specialized Clinic Dermatology, Sharjah

Syngene opens R&D centre for Amgen in Bangalore

This will be Syngene's fourth such exclusive R&D centre. It already operates dedicated R&D centres for Bristol-Myers Squibb, Abbott Nutrition and Baxter Inc

Glenmark discovers new biologic drug for cancer treatment

The company is likely to file an investigational new drug (IND) application with the US FDA for the new drug, GBR 1372, in the second half of the next financial year FY 2018